39 Paul Tudor Jones II Regeneron Pharmaceuticals Trades
Paul Tudor Jones II's position in Regeneron Pharmaceuticals is currently worth $19.7M. That's 0.15% of their equity portfolio (161st largest holding). The first Regeneron Pharmaceuticals trade was made in Q2 2013. Since then Paul Tudor Jones II bought shares 23 more times and sold shares on 23 occasions. The investor's estimated purchase price is $26.3M, resulting in a loss of 25%.
News about Regeneron Pharmaceuticals, Inc. and Paul Tudor Jones II
Regeneron: Phase III Success In Skin Cancer For Libtayo
Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success...
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
In today''s rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company ...
Assessing Biogen''s Performance Against Competitors In Biotechnology Industry
Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry...
Libtayo (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No ...